NCT03682289 2026-04-15Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsUniversity of California, San FranciscoPhase 2 Recruiting89 enrolled
NCT04739800 2026-04-13Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsNational Cancer Institute (NCI)Phase 2 Active not recruiting120 enrolled 19 charts